Core Viewpoint - A class action lawsuit has been filed against StubHub Holdings, Inc. on behalf of investors who acquired StubHub securities during the specified class period, particularly related to its September 2025 IPO [1][2]. Group 1: Lawsuit Details - The lawsuit is initiated by Berger Montague PC, representing investors who purchased StubHub securities from September 14, 2025, to November 24, 2025 [1]. - Investors have until January 23, 2026, to seek appointment as lead plaintiff representative of the class [2]. Group 2: Allegations - The complaint alleges that StubHub's IPO Registration Statement did not disclose significant changes in the timing of payments to vendors, which adversely affected the company's free cash flow [3].

NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Fermi Inc. (“Fermi” or the “Company”) (NASDAQ: FRMI).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Fermi and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On or around October 1, ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by ADC Therapeutics and its officers or directors, following a significant stock price drop after the release of clinical trial data [1][4]. Group 1: Investigation Details - Pomerantz LLP is representing investors of ADC Therapeutics and is urging them to contact the firm regarding the investigation [1]. - The investigation focuses on whether ADC Therapeutics has engaged in securities fraud or other unlawful business practices [1]. Group 2: Clinical Trial Data - On December 3, 2025, ADC Therapeutics announced updated data from the LOTIS-7 Phase 1b clinical trial for ZYNLONTA® in combination with glofitamab for patients with relapsed or refractory diffuse large B-cell lymphoma [3]. - The press release highlighted positive aspects of the data but also noted adverse events in two patients, with one being treatment-related, and reported that cytokine release syndrome occurred in 36.7% of patients across dose levels [3]. Group 3: Stock Price Reaction - Following the announcement of the clinical trial data, ADC Therapeutics' stock price fell by $0.65 per share, representing a 14.13% decrease, closing at $3.95 per share on December 3, 2025 [4].

NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of SNDL Inc. (“SNDL” or the “Company”) (NASDAQ: SNDL).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether SNDL and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On December 15, 2025, SNDL a ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Air Products and Chemicals, Inc. and its officers or directors [1] Group 1: Company Developments - On December 8, 2025, Air Products announced advanced negotiations with Yara International to combine its industrial gas capabilities and low-emission hydrogen production with Yara's ammonia production, shipping, and terminals, focusing on European demand [3] - Following the announcement, Air Products' stock price decreased by $24.64 per share, or 9.45%, closing at $236.05 per share on the same day [3] Group 2: Legal Investigation - Pomerantz LLP is representing investors of Air Products in an investigation regarding possible securities fraud or other unlawful business practices [1] - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action [2]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Aerovironment, Inc. and its officers or directors, following disappointing financial results that led to a significant drop in stock price [1][3]. Financial Performance - On December 9, 2025, Aerovironment reported earnings per share of $0.44, which was below the consensus estimate of $0.80 [3]. - The company's gross margins decreased to 20.9% from 43% in the same quarter of the previous year, with the cost of goods sold rising to 79% of revenue [3]. - Aerovironment incurred a loss of $67.4 million for the quarter, contrasting with a profit of $21.2 million in the same period the previous year [3]. Stock Market Reaction - Following the financial report, Aerovironment's stock price fell by $36.17 per share, or 12.85%, closing at $245.25 per share on December 10, 2025 [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Rezolute, Inc. and its officers or directors following disappointing clinical trial results that led to a significant drop in the company's stock price [1][3]. Group 1: Company Overview - Rezolute, Inc. is a publicly traded company on NASDAQ under the ticker RZLT [1]. - The company recently announced topline results from its Phase 3 sunRIZE study evaluating ersodetug for congenital hyperinsulinism [3]. Group 2: Clinical Trial Results - The Phase 3 study did not meet its primary endpoint, which was to assess the change in average weekly hypoglycemia events, showing only a 45% reduction in events at the highest dose of ersodetug (10 mg/kg), which was not statistically significant compared to a 40% improvement in the placebo group [3]. - The study also failed to meet its key secondary endpoint, with a 25% reduction in average daily percent time in hypoglycemia at the 10 mg/kg dose, again not statistically significant compared to a 5% increase in the placebo group [3]. Group 3: Stock Market Reaction - Following the announcement of the clinical trial results, Rezolute's stock price fell by $9.44 per share, or 87.2%, closing at $1.77 per share on December 19, 2025 [3].

Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of Ramaco Resources, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1]. Group 1: Investigation Details - The investigation is prompted by allegations from Wolfpack Research that Ramaco's Brook Mine project is a "hoax" and that the company manipulated data to misrepresent its profitability to investors [3]. - Following the allegations, Ramaco's stock price experienced a significant decline, falling by $3.81 per share, or 9.57%, closing at $36.01 per share on October 23, 2025 [3]. Group 2: Company Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of over 85 years in fighting for victims of securities fraud and corporate misconduct [3].

Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of Above Foods Ingredients Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1]. Group 1: Company Developments - On December 2, 2025, Above Food disclosed that its auditor had resigned in July at the company's request [3]. - Following the auditor's resignation announcement, Above Food's stock price fell by $0.23 per share, or 7.67%, closing at $1.69 per share on December 19, 2025 [3]. Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [4].

NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Nektar and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On December 1 ...